文献速递妇科

复发上皮性卵巢癌患者存档肿瘤与活检样本中叶酸受体α(FRα)表达的特征:靶向FRα的抗体偶联药物mirvetuximab soravtansine的I期扩展研究

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
PubMed 文献 · Gynecol Oncol · 2017-08-24

本研究为I期扩展研究,纳入27例经重度治疗的复发卵巢癌患者,评估存档肿瘤与活检样本中FRα表达的一致性,并给予mirvetuximab soravtansine 6mg/kg每3周一次。存档与活检组织FRα表达一致率为71%,治疗前后配对活检未见受体表达重大变化。确认客观缓解率为22%,最高FRα水平亚组客观缓解率达31%、无进展生存期5.4个月,较高FRα表达与更强抗肿瘤活性相关。

要点

  • 存档肿瘤与活检样本FRα表达一致率为71%,存档组织可用于患者筛选。
  • 确认客观缓解率为22%,包括2例完全缓解和4例部分缓解。
  • 最高FRα水平亚组客观缓解率31%,无进展生存期5.4个月。

核心结论

  • 活检与存档肿瘤样本中FRα表达的一致性提示存档组织可可靠识别受体阳性肿瘤,适合用于mirvetuximab soravtansine临床试验的患者选择。
  • 无论分析的组织来源如何,较高的FRα表达与更强的抗肿瘤活性相关。

研究设计与样本

  • I期扩展研究,纳入27例适合活检的复发卵巢癌患者,入组要求存档肿瘤样本FRα阳性(≥25%细胞且≥2+染色强度)。
  • 患者接受mirvetuximab soravtansine 6mg/kg每3周一次,治疗前后采集粗针活检,采用免疫组化评估FRα水平。

主要发现

  • 27例经重度治疗的患者中,6例(22%)因肿瘤细胞不足无可评估的治疗前活检。
  • 存档与活检组织FRα表达一致率为71%,配对治疗前后活检样本中未见受体表达重大变化。
  • 确认客观缓解率为22%,包括2例完全缓解和4例部分缓解。
  • 最高FRα水平亚组客观缓解率为31%,无进展生存期为5.4个月。
  • 不良事件总体为轻度(≤2级),最常见的治疗相关毒性为角膜病变(48%)、乏力(44%)、腹泻和视物模糊(各37%)。

关键数值与推荐

  • 入组要求存档肿瘤样本FRα阳性:≥25%细胞且≥2+染色强度。
  • mirvetuximab soravtansine给药剂量为6mg/kg,每3周一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients. METHODS: Patients with ovarian tumors amenable to biopsy were eligible to enroll. Eligibility included a minimum requirement of FRα positivity in archival tumor samples (≥25% of cells with ≥2+ staining intensity). Patients received mirvetuximab soravtansine at 6mg/kg once every 3weeks. Core needle biopsies were collected before and after treatment and FRα levels assessed by immunohistochemistry. Descriptive statistics were used to summarize the association between receptor expression and response. RESULTS: Twenty-seven heavily pre-treated patients were enrolled. Six individuals (22%) did not have evaluable pre-treatment biopsies due to insufficient tumor cells. The concordance of FRα expression in archival and biopsy tissues was 71%, and no major shifts in receptor expression were seen in matched pre- and post-treatment biopsy samples. Adverse events were generally mild (≤grade 2) with keratopathy (48%), fatigue (44%), diarrhea, and blurred vision (each 37%) being the most common treatment-related toxicities. The confirmed objective response rate (ORR) was 22%, including two complete responses and four partial responses. Superior efficacy measures were observed in the subset of patients with the highest FRα levels (ORR, 31%; progression-free survival, 5.4months). CONCLUSION: Concordance of FRα expression in biopsy versus archival tumor samples suggests that archival tissue can reliably identify patients with receptor-positive tumors and is appropriate for patient selection in mirvetuximab soravtansine clinical trials. Regardless of the tissue source analyzed, higher FRα expression was associated with greater antitumor activity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017. PMID: 28843653. doi:10.1016/j.ygyno.2017.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。